Biomarker panels for predicting prostate cancer outcomes
This document provides methods and materials related to assessing male mammals (e.g., humans) with prostate cancer. For example, methods and materials for predicting (1) which patients, at the time of PSA reoccurrence, will later develop systemic disease, (2) which patients, at the time of retropubic radial prostatectomy, will later develop systemic disease, and (3) which patients, at the time of systemic disease, will later die from prostate cancer are provided.
1. A method for treating prostate cancer in combination with predicting whether or not a human will later develop systemic disease associated with the prostate cancer, wherein said method comprises:
(a) obtaining a RAD21, CDKN35, CCNB15, SEC14L15, BUB1, ALAS1, KIA0196, TAF2, SFRP4, STIP1, CTHRC1, SLC44A1, IGFBP3, EDG7, FAM94B, C8orf53, and CDK10 nucleic acid expression profile for cancer tissue obtained at the time of PSA reoccurrence or retropubic radical prostatectomy from said human,
(b) prognosing said human as later developing systemic disease based on at least said expression profile, and
(c) providing early androgen ablation to said human prognosed as later developing systemic disease based on at least said expression profile.
2. The method of claim 1 , wherein said method is performed at the time of said PSA reoccurrence.
3. The method of claim 1 , wherein said method is performed at the time of said retropubic radical prostatectomy.
4. The method of claim 1 , wherein said prognosing step (b) comprises prognosing said human as later developing systemic disease based on at least said expression profile and a clinical variable.
5. The method of claim 4 , wherein said clinical variable is selected from the group consisting of a Gleason score and a revised Gleason score.
6. The method of claim 4 , wherein said clinical variable is selected from the group consisting of a Gleason score, a revised Gleason score, age at surgery, initial PSA at recurrence, use of hormone or radiation therapy after radical retropubic prostatectomy, age at PSA recurrence, the second PSA level at time of PSA recurrence, and PSA slope.
7. A method for treating prostate cancer and predicting whether or not a human, at the time of systemic disease, will later die from the prostate cancer, wherein said method comprises:
(a) obtaining a RAD21, CDKN35, CCNB15, SEC14L15, BUB1, ALAS1, KIA0196, TAF2, SFRP4, STIP1, CTHRC1, SLC44A1, IGFBP3, EDG7, FAM94B, C8orf53, and CDK10 nucleic acid expression profile for cancer tissue obtained at the time of PSA reoccurrence or retropubic radical prostatectomy from said human,
(b) prognosing said human as later dying of said prostate cancer based on at least said expression profile, and
(c) providing early androgen ablation to said human prognosed as later dying of said prostate cancer based on at least said expression profile.
8. The method of claim 7 , wherein said prognosing step (b) comprises prognosing said human as later dying of prostate cancer based on at least said expression profile and a clinical variable.
9. The method of claim 8 , wherein said clinical variable is selected from the group consisting of a Gleason score and a revised Gleason score.
10. The method of claim 8 , wherein said clinical variable is selected from the group consisting of a Gleason score, a revised Gleason score, age at surgery, initial PSA at recurrence, use of hormone or radiation therapy after radical retropubic prostatectomy, age at PSA recurrence, the second PSA level at time of PSA recurrence, and PSA slope.
11. A method for treating prostate cancer, comprising: (1) predicting whether or not a human patient, at the time of PSA reoccurrence, will later develop systemic disease, (2) predicting whether or not a human patient, at the time of retropubic radial radical prostatectomy, will later develop systemic disease, or (3) predicting whether or not a human patient, at the time of systemic disease, will later die from prostate cancer, wherein said method comprises obtaining a RAD21, CDKN3, CCNB1, SEC14L1, BUB1, ALAS1, KIAA0196, TAF2, SFRP4, STIP1, CTHRC1, SLC44A1, IGFBP3, EDG7, FAM49B, C8Orf53, and CDK10 nucleic acid expression profile for cancer tissue from the human patient, determining that the expression profile is indicative of a later development of said systemic disease or said death, and providing early androgen ablation to said human patient.